
Paul L. Crispen
M.D. | Associate Professor University of Florida
- Gainesville FL
Dr. Paul L. Crispen's clinical practice and research focuses on urothelial carcinoma.
Biography
Dr. Crispen also is an associate professor and his research interest is primarily related to improving the evaluation and treatment of patients presenting with genitourinary malignancies. To date, most of his research effort has focused on the management of bladder and kidney cancer. Additionally, he has a strong interest in involving appropriately selected patients in clinical trials which are designed to evaluate new treatment regimens and hopefully improve the care of patients at the University of Florida and beyond.
Areas of Expertise
Media Appearances
Bladder Cancer - Susan's Road to Accpetance
Hope & Healing: The UF Health Blog online
2019-05-22
“The best advice for someone diagnosed with bladder cancer is to make sure you know all of your options,” said Crispen. “I encourage patients to ask open questions to their care providers and participate in bladder cancer groups locally and nationally. Shelly Doran, a genitourinary oncology nurse navigator, has set up a local support group for patients at UF Health.
Articles
Mchanisms of immune evasion in bladder cancer
Cancer Immunology, ImmunotherapyPaul L. Crispen and Sergei Kusmartsev
2019-12-06
With the introduction of multiple new agents, the role of immunotherapy is rapidly expanding across all malignancies. Bladder cancer is known to be immunogenic and is responsive to immunotherapy including intravesical BCG and immune checkpoint inhibitors. Multiple trials have addressed the role of checkpoint inhibitors in advanced bladder cancer, including atezolizumab, avelumab, durvalumab, nivolumab and pembrolizumab (all targeting the PD1/PD-L1 pathway). While these trials have demonstrated promising results and improvements over existing therapies, less than half of patients with advanced disease demonstrate clinical benefit from checkpoint inhibitor therapy. Recent breakthroughs in cancer biology and immunology have led to an improved understanding of the influence of the tumor microenvironment on the host’s immune system.